Three BRAF V600 mutant inhibitors, namely, vemurafenib, dabrafenib and encorafenib, have been approved in combination with MEK inhibitors as a treatment regimen for patients with advanced melanoma harboring BRAF V600 mutants. Here, MAP2K7 is linked to melanoma.